Skip to Main Content

Paper Details

Exploring Predictors of Response to Dacomitinib in <i>EGFR</i>-Amplified Recurrent Glioblastoma.
JCO Precis Oncol
24
2020
Dacomitinib, EGFR, EGFR ECD, EGFR extracellular domain, EGFR gene, EGFR-Amplified Recurrent Glioblastoma, EGFR-amplified GBM, EGFRvIII, EVs, GBM, GBM tumors, PATIENTS, RNA, circulating extracellular vesicles, dacomitinib, epidermal, epidermal growth factor receptor, glioblastoma, patients, tumors, tyrosine, tyrosine kinase
Author NameAffiliation
Andrew S ChiMassachusetts General Hospital and Harvard Medical School
Patrick Y WenDana-Farber/Brigham and Women's Cancer Center and Harvard Medical School
Tom MikkelsenOntario Brain Institute
Tom MikkelsenHenry Ford Hospital
Tom MikkelsenOntario Brain Institute
Tom MikkelsenHenry Ford Hospital
David M PeereboomCleveland Clinic
Isabel Arrillaga-RomanyMassachusetts General Hospital and Harvard Medical School
Rebecca A BetenskyHarvard School of Public Health
Leonora BalajMassachusetts General Hospital and Harvard Medical School
Leonora BalajMassachusetts General Hospital and Harvard Medical School
Robert R Kitchen
Xandra O BreakefieldMassachusetts General Hospital and Harvard Medical School
Anthony J IafrateMassachusetts General Hospital and Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital and Harvard Medical School
Tracy T BatchelorMassachusetts General Hospital and Harvard Medical School
  • 1 - 16

Datasets

Release 1.2